PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July - PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July - PTC Therapeutics (NASDAQ:PTCT)

On Thursday, PTC Therapeutics, Inc. (NASDAQ:PTCT) shared new data from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. These data provide further evidence of the potential benefits of sepiapterin treatment for the full spectrum of phenylketonuria (PKU) patients. Also Read: PTC Therapeutics Inks Licensing Pact With Novartis …